Breaking News
0
NEW! Get Actionable Insights with InvestingPro+ Try 7 Days Free

Karuna Therapeutics Inc. Surges After Trial Meets Primary Endpoint

Stock Markets Aug 08, 2022 14:30
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters.
 
KRTX
-0.30%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Sam Boughedda

Premarket Monday, Karuna Therapeutics Inc . (NASDAQ:KRTX) announced positive topline results from its Phase 3 EMERGENT-2 trial, which met its primary and key secondary endpoints.

The trial evaluated the drug's efficacy, safety, and tolerability in adults with schizophrenia, with Karuna stating it demonstrated a "statistically significant and clinically meaningful 9.6-point reduction in the Positive and Negative Syndrome Scale total score compared to placebo."

Here's how analysts reacted to the news:

A Citi analyst raised the firm's price target on the stock to $280 per share from $162, reiterating a Buy rating. Citi continues to see the EMERGENT-2 results as a "near best-case scenario" that positions KarXT to be the "go-to branded antipsychotic starting in schizophrenia and possibly beyond."

"We see a multi-billion dollar peak sales opportunity in just those two indications, and despite the move today, we think shares could continue to run over the next few weeks as buy-side starts giving the company credit for KarXT's broader potential," explained the analyst.

A Wedbush analyst maintained an Outperform rating and $178 price target on the stock, telling investors they anticipate a positive stock reaction following the data. "With the data offering validation of the mechanism and strategy, and KarXT representing a novel mechanism of action, we do think physicians will be excited to use the drug," said the analyst.

A William Blair analyst kept an Outperform rating on the stock, explaining in a research note that "efficacy was driven by statistically significant improvements in both positive and negative symptoms and we expect additional data on cognition to come later."

"Combining this efficacy profile beat with KarXT's differentiated novel cholinergic mechanism should have shares up materially today and our bull case heading into the data was a greater than $200 stock," added the analyst.

Finally, an RBC Capital Markets analyst, who has an Outperform rating and $160 price target on Karuna shares, told investors the data, at first glance, looks to have lived up to and likely exceeded high Street expectations.

"No major safety red flags from what we can tell initially from the press release and slide deck- Some GI effects and cholinergic related AEs but nothing that looks like it would derail the program; no syncope or major differences in HR/BP effects previously observed, and profile continues to look very differentiated from existing antipsychotics which we continue to believe along with strong efficacy will make KarXT a treatment of choice in schizophrenia, generating out year sales of $1.3B on our estimates," wrote the analyst.

Karuna shares surged 64% Monday, hitting an all-time high.

Karuna Therapeutics Inc. Surges After Trial Meets Primary Endpoint
 

Related Articles

Today's Most Important Upgrades
Today's Most Important Upgrades By Investing.com - Oct 06, 2022

By Davit Kirakosyan Oppenheimer upgraded Verizon Communications (NYSE:VZ) to Outperform from Perform with a price target of $50.00, anticipating gradual stabilization-to-growth...

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email